Sun Pharmaceutical Industries Limited has announced new long-term data for LEQSELVI® (deuruxolitinib) in adults with severe alopecia areata at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The company said LEQSELVI was featured in seven presentations, including data from a European open-label extension study evaluating treatment for up to two years.
The featured oral presentation focused on the long-term safety profile of LEQSELVI in adults with severe alopecia areata. According to the company, the safety profile through two years remained generally consistent with previous clinical experience. Most treatment-emergent adverse events were mild or moderate, while treatment discontinuations because of adverse events were uncommon. No deaths, thrombosis or major adverse cardiovascular events were reported among patients receiving the FDA-approved 8 mg twice-daily dose in the study.
Long-term efficacy data presented at the congress showed that scalp hair regrowth could be maintained through Week 108 among patients receiving LEQSELVI in the European open-label extension study.
Among patients who had responded to treatment at baseline, maintained their response at Week 52 and continued in the study, 93.9% maintained their response at Week 108. The company also reported that 76.6% of patients who were nonresponders at baseline achieved a response by Week 52. Among these patients who continued after achieving a response, 96.8% maintained their response through Week 108.
The response assessment used the Severity of Alopecia Tool (SALT). A SALT score of 100 represents total scalp hair loss, while a score of 0 represents no scalp hair loss.
Sun Pharma said additional pooled post-hoc analyses from the THRIVE-AA1 and THRIVE-AA2 studies showed consistent efficacy across clinically relevant patient subgroups. These included patients with eyebrow, eyelash or nail involvement, as well as patients with both shorter- and longer-duration disease episodes.
According to Arash Mostaghimi, Vice Chair of Clinical Trials and Innovation and Associate Professor of Dermatology at Brigham and Women's Hospital, the findings provide evidence of durable efficacy and maintenance of response over time, supporting the potential role of deuruxolitinib as a long-term treatment option for eligible adults with severe alopecia areata.
The LEQSELVI data were part of 22 presentations from Sun Pharma covering its dermatology and immunology portfolio at EADV 2026. The company said the presentations provide additional insights into long-term tolerability, durability of response and maintenance of clinical benefit in adults with severe alopecia areata.
LEQSELVI (deuruxolitinib) is an oral selective JAK1 and JAK2 inhibitor approved by the U.S. FDA for the treatment of adults with severe alopecia areata. Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, resulting in partial or complete hair loss.
Sun Pharma's release notes that LEQSELVI affects the immune system and can reduce the body's ability to fight infections. The prescribing information includes warnings concerning serious infections, tuberculosis, certain cancers, blood clots and major cardiovascular events in certain higher-risk patients. Patients are also advised to undergo appropriate testing and blood monitoring before and during treatment.
The company states that LEQSELVI should be taken twice daily, with or without food, and that the most common side effects reported include acne, headache, nasopharyngitis, increased blood creatine phosphokinase, increased cholesterol, tiredness, weight gain, thrombocytosis, anemia, skin and soft-tissue infections, neutropenia and herpes simplex.
